Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Read-GeneWAR:RDG 80 OCF Margin % is 13.23% as of Mar. 2026, which is 2977% above its 10-year median of 0.43. GuruFocus rates WAR:RDG with a GF Score™ of 80/100 and a GF Value™ of zł6.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 950 Biotechnology companies, Read-Gene ranks better than 67.79% on this metric.
The historical rank and industry rank for Read-Gene's OCF Margin % or its related term are showing as below:
WAR:RDG'
s OCF Margin % Range Over the Past 10 Years
Min: -36 Med: 0.43 Max: 17.38
Current: -0.6
During the past 13 years, the highest OCF Margin % of Read-Gene was 17.38%. The lowest was -36.00%. And the median was 0.43%.
WAR:RDG's OCF Margin % is ranked better than 67.79% of 950
companies
in the Biotechnology industry
Industry Median: -68.59
vs WAR:RDG: -0.60
Read-Gene OCF Margin % Related Terms
Read-Gene OCF Margin % Historical Data
* Premium members only.
The historical data trend for Read-Gene's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RDG vs VRTX, REGN, RVMD: OCF Margin % Comparison
For the Biotechnology subindustry, Read-Gene's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Read-Gene OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Read-Gene's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Read-Gene's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Read-Gene (WAR:RDG) has a OCF Margin % of 13.23% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Read-Gene and its competitors. This is 2977% above median its historical median of 0.43. According to the industry distribution chart, Read-Gene ranks #306 out of 950 companies in the Biotechnology industry, placing it in the top 32.2%.
Is Read-Gene's OCF Margin % too high?
Read-Gene's current OCF Margin % of 13.23% is 2977% above median its 10-year median of 0.43. Based on the distribution chart, Read-Gene ranks #306 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Read-Gene has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Read-Gene's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Read-Gene ranks #306 out of 950 companies for OCF Margin %. This puts Read-Gene in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Read-Gene and its competitors. Read-Gene's current OCF Margin % is 13.23%, which is 2977% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Read-Gene stock overvalued right now?
Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.37, compared to a current price of zł4.86 — trading 23.7% below its estimated fair value. The current OCF Margin % is 13.23%, which is 2977% above median its 10-year median of 0.43. Read-Gene's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current OCF Margin % is 13.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Read-Gene (WAR:RDG) Overvalued in 2026?
Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued.
The current stock price of zł4.86 is trading 23.7% below its estimated GF Value™ of zł6.37.
GuruFocus considers Read-Gene to be Modestly Undervalued.
Key valuation signals for WAR:RDG:
OCF Margin %: 13.23% (2977% above median its 10-year median of 0.43)
GF Value™: zł6.37 vs. price of zł4.86 (23.7% below fair value)
No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
80GF Score
Get the complete analysis for WAR:RDG
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RDG has been successfully added to your 
